Tests elecoglipron for weight management in adults with obesity or overweight
Tests elecoglipron against placebo in adults with excess weight, with or without diabetes.
Key facts
- Who runs it
- AstraZeneca
- Where
- Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, and Suwon, South KoreaSee the 8 sitesAlso in 18 other countries, 262 sites
- Trial code
- Registry title
- A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 4,500 people, planned
- Started
- 29 Jun 2026
- Expected to end
- 30 Jul 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Elecoglipron
- Placebo
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight and at least one weight-related health problem. Study 1 is for people without type 2 diabetes (T2DM). Study 2 is for people with T2DM.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Study 1: BMI 30 kg/m2 or more, or BMI from 25 kg/m2 to under 30 kg/m2 with high blood pressure, prediabetes, abnormal blood fats, heart or blood vessel disease, or sleep apnea. Study 2: BMI 25 kg/m2 or more and T2DM (diagnosed, or HbA1c 6.5% (48 mmol/mol) or higher at screening).
- Earlier treatment
- Body weight must have been stable for 90 days before screening (within 5% change). People must have tried at least once, without success, to lose weight by diet.
- Biomarker or test result
- Study 2 only: HbA1c 6.5% (48 mmol/mol) or higher at screening if T2DM was not diagnosed before.
Main reasons for not taking part
- Study 1: diagnosed type 1 or type 2 diabetes
- Study 2: type 1 diabetes
- Study 2: HbA1c 10% (86 mmol/mol) or higher at screening
- Study 2: treatment for diabetic eye disease, or more than one severe low blood sugar episode in the past 180 days
- Past or present pancreatitis (some exceptions), or medullary thyroid cancer or multiple endocrine neoplasia type 2 in the person or close family
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Legal age of consent and at least 18 years old
- Study 1 -; BMI ≥ 30 kg/m2 or; 25 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities:; Hypertension; Prediabetes; Dyslipidemia; Cardiovascular disease; Obstructive sleep apnea
- Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:; Established diagnosis of T2DM; Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
- Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Who cannot take part
- History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
- History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
- Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:; T1DM; HbA1c ≥ 10% (86 mmol/mol) at the screening visit; Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
- Study 1 - Established diagnosis of T1DM or T2DM
Where in South Korea
Also in 18 other countries, 262 sites
- BusanHospital not named in the registryNo longer taking part
- DaeguHospital not named in the registryNot yet recruiting
- Goyang-siHospital not named in the registryTaking people
- Gyeonggi-doHospital not named in the registryTaking people
- IncheonHospital not named in the registryTaking people
- Jongno-guHospital not named in the registryTaking people
- SeoulHospital not named in the registryNot yet recruiting
- SuwonHospital not named in the registryTaking people
About the trial
What the trial wants to find out
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).
The 3 groups in the trial
- Arm 1 - Dose 1Treatment being tested
Active IMP
Treatment: Elecoglipron
- Arm 2 - Dose 2Treatment being tested
Active IMP
Treatment: Elecoglipron
- Arm 3 - PlaceboPlacebo, for comparison
Placebo matching elecoglipron
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
- Plain-language title
- Tests elecoglipron for weight management in adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 October 2026